Mosaic ImmunoEngineering Inc.
CPMV · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 5/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -9.63% | -9.92% | 0.00% | -109.08% |
| EV / EBITDA | -3.58 | -2.10 | 0.00 | 0.12 |
| Quality | ||||
| ROIC | 71.93% | 177.51% | 0.00% | -43.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.26 | 0.29 | 0.18 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -1.60% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.44 | -0.15 | 0.00 | 1.07 |
| Interest Coverage | -37.68 | -121.55 | 0.00 | -11.69 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |